Desde 500€ puedes invertir en Biocross a través de Blockchain
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
Biocross presents at Bio-Europe 2016
Biocross S.L., a biotechnology company focused on the development of innovative technologies for the diagnosis of Alzheimer’s disease and the identification of at-risk individuals, today announced that their Chief Executive Officer Matt Mittino will present the company’s projects at BIO-Europe 2016, the 22nd Annual International Partnering Conference, to be held Cologne, Germany from November 7–9, 2016.
Biospain 2016 – Company Presentation
Biospain has become the main scientific, social, commercial, and industrial meeting point of the biotechnological sector and the primary platform for the international presentation of advances in Spanish biotechnology.
The Spanish entrepreneurs fighting against Alzheimer’s
The diagnosis of Alzheimer’s disease is established through a series of neuropsychological tests, images obtained by MRI or CT scan, and the analysis of markers obtained by lumbar puncture.
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96